April 13, 2023
Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases
Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners. Proceeds to advance AER-01 into the clinic for treatment of chronic obstructive pulmonary disease (COPD); unique targeted approach to treating patients affected by mucus plugs.